- Home
- SQNS vs GLSI Comparison
SQNS vs GLSI Comparison
Compare SQNS & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SQNS
- GLSI
- Stock Information
- Founded
- SQNS 2003
- GLSI 2006
- Country
- SQNS France
- GLSI United States
- Employees
- SQNS N/A
- GLSI N/A
- Industry
- SQNS Semiconductors
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- SQNS Technology
- GLSI Health Care
- Exchange
- SQNS Nasdaq
- GLSI Nasdaq
- Market Cap
- SQNS 140.2M
- GLSI 149.5M
- IPO Year
- SQNS 2011
- GLSI 2020
- Fundamental
- Price
- SQNS $9.96
- GLSI $11.26
- Analyst Decision
- SQNS Buy
- GLSI Strong Buy
- Analyst Count
- SQNS 1
- GLSI 1
- Target Price
- SQNS $35.00
- GLSI $39.00
- AVG Volume (30 Days)
- SQNS 376.5K
- GLSI 91.2K
- Earning Date
- SQNS 11-04-2025
- GLSI 11-13-2025
- Dividend Yield
- SQNS N/A
- GLSI N/A
- EPS Growth
- SQNS N/A
- GLSI N/A
- EPS
- SQNS 18.54
- GLSI N/A
- Revenue
- SQNS $37,325,000.00
- GLSI N/A
- Revenue This Year
- SQNS N/A
- GLSI N/A
- Revenue Next Year
- SQNS $89.05
- GLSI N/A
- P/E Ratio
- SQNS $0.53
- GLSI N/A
- Revenue Growth
- SQNS 32.07
- GLSI N/A
- 52 Week Low
- SQNS $7.30
- GLSI $8.06
- 52 Week High
- SQNS $58.30
- GLSI $15.47
- Technical
- Relative Strength Index (RSI)
- SQNS 48.86
- GLSI 53.48
- Support Level
- SQNS $9.40
- GLSI $9.73
- Resistance Level
- SQNS $10.00
- GLSI $10.57
- Average True Range (ATR)
- SQNS 0.58
- GLSI 0.57
- MACD
- SQNS 0.25
- GLSI 0.02
- Stochastic Oscillator
- SQNS 55.66
- GLSI 67.77
About SQNS Sequans Communications S.A.
Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its offer 5G/4G chips and modules fully optimized for non-smartphone devices. The company covers applications such as smart mobility and logistics, smart utility meters, smart cities, smart industries, e-health and wellness, and smart homes to name few. The Company has one operating segment, which is the design and marketing of semiconductor components for cellular wireless systems. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.